Development of virus-specific immune responses in SHIVKU-infected macaques treated with PMPA

Anil Kumar, Shilpa J Buch, Larry Foresman, Norbert Bischofberger, Jeffrey D. Lifson, Opendra Narayan

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to the suppression of HIV viremia below the threshold of detection for several years. However, impact of HAART on reconstitution of virus-specific immune responses remains poorly understood. In this study, four macaques were infected with pathogenic SHIVKU. One week postinoculation two of the four animals were treated with PMPA [9-R-(2-phosphophomethoxypropyl)adenine] daily for 83 days. Two other macaques, that did not receive treatment, exhibited explosive virus replication accompanied by a near total loss of CD4+ T cells and succumbed to AIDS-related complications within 6 months of infection. These animals did not develop any virus-specific immune responses. On the contrary, the animals that received PMPA showed transient loss of CD4+ T cells that recovered during the treatment period. The virus burden declined below the level of detection that rebounded soon after cessation of PMPA therapy. The virus replicated productively for several weeks before both animals controlled the productive replication of virus. This control of virus replication was found to be associated with the development of virus-specific neutralizing antibodies, T-helper cells, and CTLs. Although PMPA did not eliminate virus from the animals, it provided them with enough time to mount virus-specific immune responses that eventually controlled the virus replication in the blood. Our results suggest that antiretroviral therapy, if initiated early during infection, would help the host in mounting virus-specific immune responses that might control productive replication of the virus.

Original languageEnglish (US)
Pages (from-to)97-108
Number of pages12
JournalVirology
Volume279
Issue number1
DOIs
StatePublished - Jan 20 2001

Fingerprint

Macaca
Adenine
Viruses
Virus Replication
Highly Active Antiretroviral Therapy
T-Lymphocytes
Therapeutics
Viremia
Helper-Inducer T-Lymphocytes
Infection
Neutralizing Antibodies
Acquired Immunodeficiency Syndrome
HIV

Keywords

  • AIDS
  • Antibodies
  • Antiretroviral treatment
  • CTL
  • In vivo animal models
  • SHIV

ASJC Scopus subject areas

  • Virology

Cite this

Kumar, A., Buch, S. J., Foresman, L., Bischofberger, N., Lifson, J. D., & Narayan, O. (2001). Development of virus-specific immune responses in SHIVKU-infected macaques treated with PMPA. Virology, 279(1), 97-108. https://doi.org/10.1006/viro.2000.0710

Development of virus-specific immune responses in SHIVKU-infected macaques treated with PMPA. / Kumar, Anil; Buch, Shilpa J; Foresman, Larry; Bischofberger, Norbert; Lifson, Jeffrey D.; Narayan, Opendra.

In: Virology, Vol. 279, No. 1, 20.01.2001, p. 97-108.

Research output: Contribution to journalArticle

Kumar, A, Buch, SJ, Foresman, L, Bischofberger, N, Lifson, JD & Narayan, O 2001, 'Development of virus-specific immune responses in SHIVKU-infected macaques treated with PMPA', Virology, vol. 279, no. 1, pp. 97-108. https://doi.org/10.1006/viro.2000.0710
Kumar, Anil ; Buch, Shilpa J ; Foresman, Larry ; Bischofberger, Norbert ; Lifson, Jeffrey D. ; Narayan, Opendra. / Development of virus-specific immune responses in SHIVKU-infected macaques treated with PMPA. In: Virology. 2001 ; Vol. 279, No. 1. pp. 97-108.
@article{7bae05f79d674c57a6515a4c198a6bf9,
title = "Development of virus-specific immune responses in SHIVKU-infected macaques treated with PMPA",
abstract = "Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to the suppression of HIV viremia below the threshold of detection for several years. However, impact of HAART on reconstitution of virus-specific immune responses remains poorly understood. In this study, four macaques were infected with pathogenic SHIVKU. One week postinoculation two of the four animals were treated with PMPA [9-R-(2-phosphophomethoxypropyl)adenine] daily for 83 days. Two other macaques, that did not receive treatment, exhibited explosive virus replication accompanied by a near total loss of CD4+ T cells and succumbed to AIDS-related complications within 6 months of infection. These animals did not develop any virus-specific immune responses. On the contrary, the animals that received PMPA showed transient loss of CD4+ T cells that recovered during the treatment period. The virus burden declined below the level of detection that rebounded soon after cessation of PMPA therapy. The virus replicated productively for several weeks before both animals controlled the productive replication of virus. This control of virus replication was found to be associated with the development of virus-specific neutralizing antibodies, T-helper cells, and CTLs. Although PMPA did not eliminate virus from the animals, it provided them with enough time to mount virus-specific immune responses that eventually controlled the virus replication in the blood. Our results suggest that antiretroviral therapy, if initiated early during infection, would help the host in mounting virus-specific immune responses that might control productive replication of the virus.",
keywords = "AIDS, Antibodies, Antiretroviral treatment, CTL, In vivo animal models, SHIV",
author = "Anil Kumar and Buch, {Shilpa J} and Larry Foresman and Norbert Bischofberger and Lifson, {Jeffrey D.} and Opendra Narayan",
year = "2001",
month = "1",
day = "20",
doi = "10.1006/viro.2000.0710",
language = "English (US)",
volume = "279",
pages = "97--108",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Development of virus-specific immune responses in SHIVKU-infected macaques treated with PMPA

AU - Kumar, Anil

AU - Buch, Shilpa J

AU - Foresman, Larry

AU - Bischofberger, Norbert

AU - Lifson, Jeffrey D.

AU - Narayan, Opendra

PY - 2001/1/20

Y1 - 2001/1/20

N2 - Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to the suppression of HIV viremia below the threshold of detection for several years. However, impact of HAART on reconstitution of virus-specific immune responses remains poorly understood. In this study, four macaques were infected with pathogenic SHIVKU. One week postinoculation two of the four animals were treated with PMPA [9-R-(2-phosphophomethoxypropyl)adenine] daily for 83 days. Two other macaques, that did not receive treatment, exhibited explosive virus replication accompanied by a near total loss of CD4+ T cells and succumbed to AIDS-related complications within 6 months of infection. These animals did not develop any virus-specific immune responses. On the contrary, the animals that received PMPA showed transient loss of CD4+ T cells that recovered during the treatment period. The virus burden declined below the level of detection that rebounded soon after cessation of PMPA therapy. The virus replicated productively for several weeks before both animals controlled the productive replication of virus. This control of virus replication was found to be associated with the development of virus-specific neutralizing antibodies, T-helper cells, and CTLs. Although PMPA did not eliminate virus from the animals, it provided them with enough time to mount virus-specific immune responses that eventually controlled the virus replication in the blood. Our results suggest that antiretroviral therapy, if initiated early during infection, would help the host in mounting virus-specific immune responses that might control productive replication of the virus.

AB - Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to the suppression of HIV viremia below the threshold of detection for several years. However, impact of HAART on reconstitution of virus-specific immune responses remains poorly understood. In this study, four macaques were infected with pathogenic SHIVKU. One week postinoculation two of the four animals were treated with PMPA [9-R-(2-phosphophomethoxypropyl)adenine] daily for 83 days. Two other macaques, that did not receive treatment, exhibited explosive virus replication accompanied by a near total loss of CD4+ T cells and succumbed to AIDS-related complications within 6 months of infection. These animals did not develop any virus-specific immune responses. On the contrary, the animals that received PMPA showed transient loss of CD4+ T cells that recovered during the treatment period. The virus burden declined below the level of detection that rebounded soon after cessation of PMPA therapy. The virus replicated productively for several weeks before both animals controlled the productive replication of virus. This control of virus replication was found to be associated with the development of virus-specific neutralizing antibodies, T-helper cells, and CTLs. Although PMPA did not eliminate virus from the animals, it provided them with enough time to mount virus-specific immune responses that eventually controlled the virus replication in the blood. Our results suggest that antiretroviral therapy, if initiated early during infection, would help the host in mounting virus-specific immune responses that might control productive replication of the virus.

KW - AIDS

KW - Antibodies

KW - Antiretroviral treatment

KW - CTL

KW - In vivo animal models

KW - SHIV

UR - http://www.scopus.com/inward/record.url?scp=0035915990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035915990&partnerID=8YFLogxK

U2 - 10.1006/viro.2000.0710

DO - 10.1006/viro.2000.0710

M3 - Article

VL - 279

SP - 97

EP - 108

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -